Sol-Gel Technologies Ltd
SLGL
Company Profile
Business description
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.
Contact
7 Golda Meir Street
Weizmann Science Park
Ness Ziona7403650
ISRT: +972 89313433
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
34
Stocks News & Analysis
stocks
Investment decisions in overvalued bank drive strong results
Shares fall despite a broadly unchanged outlook.
stocks
Overvalued ASX share hurt by normalising conditions
Investors overly optimisitc about future prospects.
stocks
After earnings, is Amazon stock a buy, a sell, or fairly valued?
With temperature on tariffs easing and a raised fair value estimate, here’s what we think of Amazon’s results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,109.40 | 52.50 | 0.58% |
| CAC 40 | 8,065.79 | 115.61 | 1.45% |
| DAX 40 | 24,014.26 | 444.30 | 1.89% |
| Dow JONES (US) | 46,987.10 | 74.80 | 0.16% |
| FTSE 100 | 9,780.23 | 97.66 | 1.01% |
| HKSE | 26,649.06 | 407.23 | 1.55% |
| NASDAQ | 23,004.54 | 49.46 | -0.21% |
| Nikkei 225 | 50,911.76 | 635.39 | 1.26% |
| NZX 50 Index | 13,617.48 | 18.27 | 0.13% |
| S&P 500 | 6,728.80 | 8.48 | 0.13% |
| S&P/ASX 200 | 8,835.90 | 44.10 | 0.50% |
| SSE Composite Index | 4,018.60 | 21.04 | 0.53% |